Characterizing tumor invasiveness of glioblastoma using multiparametric magnetic resonance imaging.
Boonzaier, Natalie R
Journal of neurosurgery
American Association of Neurological Surgeons
MetadataShow full item record
Li, C., Wang, S., Yan, J., Torheim, T., Boonzaier, N. R., Sinha, R., Matys, T. M., et al. (2019). Characterizing tumor invasiveness of glioblastoma using multiparametric magnetic resonance imaging.. Journal of neurosurgery, 1-8. https://doi.org/10.3171/2018.12.jns182926
Objective To characterize the abnormalities revealed by diffusion tensor imaging (DTI) using magnetic resonance spectroscopy and perfusion imaging, and to evaluate the prognostic value of a proposed quantitative measure of tumor invasiveness by combining contrast-enhancing and DTI abnormalities in glioblastoma patients. Methods Eighty-four glioblastoma patients were recruited pre-operatively. DTI was decomposed into isotropic (p) and anisotropic (q) components. The relative cerebral blood volume (rCBV) were calculated from the dynamic susceptibility contrast imaging. Values of N-acetyl aspartate (NAA), myoinositol (mIns), choline (Cho), lactate (Lac) and glutamate + glutamine (Glx) were measured from multivoxel magnetic resonance spectroscopy and normalized as ratios to creatine (Cr). Tumor regions of interest (ROIs) were manually segmented from the contrast-enhancing T1-weighted (CE-ROI) and DTI-q (q-ROI) maps. Perfusion and metabolic characteristics of above ROIs were measured and compared. Relative invasiveness coefficient (RIC) was calculated as a ratio of the characteristics radius of CE-ROI and q-ROI. The prognostic significance of RIC was tested using Kaplan-Meier and multivariate Cox regression analyses. Results The Cho/Cr, Lac/Cr and Glx/Cr in q-ROI were significantly higher than CE-ROI (P = 0.004, P = 0.005 and P = 0.007, respectively). CE-ROI had significantly higher rCBV values than q-ROI (P < 0.001). A higher RIC was associated with worse survival in multivariate overall survival (OS) model (hazard ratio [HR] = 1.40, 95% CI: 1.06-1.85, P = 0.016) and progression-free survival (PFS) model (HR = 1.55, 95% CI: 1.16-2.07, P = 0.003). An RIC cutoff value of 0.89 significantly predicted shorter OS (median 244 and 384 days, respectively; P = 0.002) and PFS (median 406 and 605 days, respectively; P = 0.001). Conclusions DTI-q abnormalities displayed higher tumor load and hypoxic signatures compared to contrast-enhancing abnormalities, whereas contrast enhancing regions potentially represented the proliferation front. Integrating the invasion extents of DTI-q and contrast enhancing volume into clinical practice may lead to improved treatment efficacy.
Cancer Research UK (C14303/A17197)
Cancer Research UK (19274)
Embargo Lift Date
External DOI: https://doi.org/10.3171/2018.12.jns182926
This record's URL: https://www.repository.cam.ac.uk/handle/1810/290738